The report "Antibody Therapeutics Market by Format (Monoclonal, Polyclonal, Antibody Fragment, Bispecific), Disease area (Oncology, Autoimmune & Inflammatory, Neurology, Hematology, Infectious), Source (Human, Chimeric), Route (IV, SC) - Global Forecast to 2028 ", is projected to reach USD 479.0 billion by 2028 from USD 247.3 billion in 2023, at a CAGR of 14.1% during the forecast period. The growing advancements in antibody engineering, the growing demand for oncology antibody therapeutics and the increasing clinical pipeline focus on antibody therapeutics are the factors supporting the growth of this market.
Browse 313 market data Tables and 51 Figures spread through 306 Pages and in-depth TOC on "Antibody Therapeutics Market by Format (Monoclonal, Polyclonal, Antibody Fragment, Bispecific), Disease area (Oncology, Autoimmune & Inflammatory, Neurology, Hematology, Infectious), Source (Human, Chimeric), Route (IV, SC) - Global Forecast to 2028 "
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/antibody-therapeutics-market-178852478.html
Monoclonal antibodies subsegment is the fastest-growing of the antibody therapeutics market by format.
Among the format subsegments, the antibody therapeutics market is segmented into monoclonal antibodies, polyclonal antibodies, antibody fragments, bispecific antibodies, and other novel antibody therapies. In 2022, the monoclonal antibodies segment accounted for the fastest-growing market of the format segment. This can be attributed to factors such as the presence of a large number of pipeline monoclonal antibodies and benefits such as target specificity offered by mAbs among others.
Oncology is the fastest-growing segment of the antibody therapeutics market by disease area.
Among the disease area subsegments, the antibody therapeutics market is segmented into autoimmune & inflammatory diseases, oncology, hematology, infectious diseases, osteology, immunology, neurology, and other disease areas. In 2022, the oncology segment accounted for the fastest-growing share of the disease area segment of the antibody therapeutics market. Growth in this market segment can be attributed to one of the major factors which is the presence of a large number of oncology therapeutics products in the clinical pipeline.
Europe: The second-largest region in the antibody therapeutics market.
The European market is the second-largest antibody therapeutics market globally. One of the major factors supporting the high growth of the European antibody therapeutics market is the advancements in antibody therapy research in the region. Major countries contributing to this growth include Germany, the UK and France. Moreover, the presence of some of the key market players such as F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (UK), and Merck KGaA (Germany) among others in the region, is another factor supporting the growth of the European antibody therapeutics market.
The market for antibody therapeutics market is consolidated, with key players strategizing to capture the market. Prominent players in the antibody therapeutics market are F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (US), Johnson & Johnson (US), Merck KGaA (Germany), Bristol-Myers Squibb (US), AstraZeneca (UK), Sanofi (France), Regeneron Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Biogen Inc. (US) among others.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
